Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
New words:
ab, abbreviated, abdomen, abnormal, ACCI, acronym, advocacy, Amini, AMM, Amsterdam, anchored, antigen, Apr, armpit, autonomy, benign, biomarker, bispecific, blaze, blockage, bone, bright, Brunswick, bulge, Cadre, censoring, CFR, Christensen, clawback, Clayton, cliff, CNS, codification, compound, controversy, countersigned, CRO, curative, cyber, cyst, cytoplasm, dataset, daunting, decade, decentralized, designee, diagnostic, differentiation, Dilemma, diploma, discipline, disclaimer, distal, distort, DLT, DOR, dosimetrist, doublet, elevated, emitted, endoscopic, era, erroneously, escape, exceedingly, excitement, exerting, exponentially, familiar, firmly, fluid, forever, freedom, fundamental, George, grateful, Greek, grew, groin, groundswell, groundwork, GTCA, hepatocarcinoma, hierarchy, hormone, HSR, hyperexcitability, ICD, IEC, immuno, immunological, incumbent, ingredient, int, Interestingly, Irene, isolated, Jama, Jansen, Janssen, JJDC, Johnson, JSC, Kayitalire, KPMG, Latin, laying, leaseback, LEEM, Leeman, lip, literally, longstanding, lump, lymph, lymphatic, Lysosomal, MA, macroeconomic, magnetic, mainstream, map, Marill, maximize, maximizing, mediation, Membrane, micronuclei, mind, modality, Moye, MRI, MSA, multicenter, muscle, nasal, nasopharynx, neurobiology, neurological, neuronal, neuropathic, newer, NJ, nodal, node, novation, NV, oncologist, Oocuity, outer, outset, overtime, parameter, particle, partly, pattern, paving, Permeabilization, perspective, Pharmaceutica, pharmacological, physicist, physiological, PIPE, Plot, poised, poorer, possession, posture, prognostic, proliferative, prolonged, prophylactic, proposition, proton, radiobiologist, radiological, radiology, Radiother, radiotherapist, randomly, ray, reactor, reallocation, recognizable, reconstruction, renegotiation, resilience, Resonance, revolution, revolutionary, risen, rooted, runway, salivary, Scotland, sentiment, Shia, simply, soundly, SPA, specialty, stand, Stephan, stood, stream, strive, subcontract, subtype, superficial, supposed, technician, temporarily, testament, Thirteen, thy, tirelessly, twentieth, ultrasound, underpinning, unequivocal, unveil, vessel, vision, vol, Waterfall, Zhang
Removed:
adult, amending, amplifying, Ave, blurred, Boston, breached, caption, CCRT, CEO, clean, cluster, cole, conceptual, concerted, conclusive, Condomine, confirmed, consecutive, covid, creating, cytokine, demarcation, diagnosing, diarrhea, disperse, electronic, encouraging, enriched, eurozone, excessive, exploring, Faubourg, floor, frontline, Fulfilling, geographic, Gestion, Grande, graph, hemorrhage, Institut, intratumor, invade, Investissement, irreparable, iTech, judged, justice, Keytruda, lapsed, lethal, Lexington, liaison, Macau, Matignon, MEDCL, Medincell, ordinarily, Pacific, phenomena, posed, proliferation, radiosensitivity, receptor, reclassification, regulate, revision, Saint, sensing, signaling, tailor, throat, tongue, tract, transferability, unconfirmed, urinary
Filing tables
Filing exhibits
- 20-F Annual report (foreign)
- 2.4 EX-2.4 Registration Rights Agreement (Executed Sep 11 2023)
- 2.5 EX-2.5 Omnibus Restricted Ads Letter Agreement
- 4.2.2 EX-4.2.2 Bei - Nanobiotix - Amendment to the Finance Contract
- 4.3.2 EX-4.3.2 Bei - Nanobiotix - Amendment to the Royalty Agreement
- 4.5.1 EX-4.5.1 Assignment Agreement of the Asia Development Agreement
- 4.6 EX-4.6 Janssen Agreement
- 4.22 EX-4.22 2023 Stock Option Plan
- 12.1 EX-12.1 Certification by the Principal Executive Officer
- 12.2 EX-12.2 Certification by the Principal Financial Officer
- 13.1 EX-13.1 Certification by the Principal Executive Officer
- 13.2 EX-13.2 Certification by the Principal Financial Officer
- 15.1 EX-15.1 Consent of Ernst & Young Et Autres
- 15.2 EX-15.2 Letter from Ernst & Young Et Autres Pursuant to Item 16F
- 97 EX-97 Compensation Recoupment Policy
- Download Excel data file
- View Excel data file
NBTX similar filings
Filing view
External links
Exhibit 15.2
Securities and Exchange Commission
100 F Street, N.E.
Washington, DC 20549
Ladies and Gentlemen,
We have read Item 16F. Change in Registrant’s Certifying Accountant on pages 163 of Form 20-F dated April 24, 2024, of Nanobiotix S.A. and are in agreement with the statements contained in paragraphs one, four, and six. Regarding the registrant's statement concerning a material weakness in internal control over financial reporting as disclosed in Item 15.B of the Company’s 2022 Annual Report on Form 20-F and Item 15.B of the Company's 2023 Annual Report on Form 20-F, included in paragraph four on page 163 therein, we had considered such matter in determining the nature, timing, and extent of procedures performed in our audit of the registrant's 2022 and 2023 financial statements. We have no basis to agree or disagree with other statements of the registrant contained therein.
/s/ Ernst & Young et Autres
Paris-La Défense, France
April 24, 2024